TY - JOUR
T1 - Design of Class I/IV Bromodomain-Targeting Degraders for Chromatin Remodeling Complexes
AU - Zahid, Huda
AU - Costello, Jeff P.
AU - Li, Yao
AU - Kimbrough, Jennifer R.
AU - Actis, Marisa
AU - Rankovic, Zoran
AU - Yan, Qin
AU - Pomerantz, William C.K.
N1 - Publisher Copyright:
© 2023 American Chemical Society.
PY - 2022
Y1 - 2022
N2 - Targeted protein degradation is an emerging technology that can be used for modulating the activity of epigenetic protein targets. Among bromodomain-containing proteins, a number of degraders for the BET family have been developed, while non-BET bromodomains remain underexplored. Several of these proteins are subunits in chromatin remodeling complexes often associated with oncogenic roles. Here, we describe the design of class I (BPTF and CECR2) and IV (BRD9) bromodomain-targeting degraders based on two scaffolds derived from pyridazinone and pyrimidine-based heterocycles. We evaluate various exit vectors and linkers to identify analogues that demonstrate selectivity within these families. We further use an in-cell NanoBRET assay to demonstrate that these heterobifunctional molecules are cell-permeable, form ternary complexes, and can degrade nanoluciferase-bromodomain fusions. As a first example of a CECR2 degrader, we observe that our pyrimidine-based analogues degrade endogenous CECR2 while showing a smaller effect on BPTF levels. The pyridazinone-based compounds did not degrade BPTF when observed through Western blotting, further supporting a more challenging target for degradation and a goal for future optimization.
AB - Targeted protein degradation is an emerging technology that can be used for modulating the activity of epigenetic protein targets. Among bromodomain-containing proteins, a number of degraders for the BET family have been developed, while non-BET bromodomains remain underexplored. Several of these proteins are subunits in chromatin remodeling complexes often associated with oncogenic roles. Here, we describe the design of class I (BPTF and CECR2) and IV (BRD9) bromodomain-targeting degraders based on two scaffolds derived from pyridazinone and pyrimidine-based heterocycles. We evaluate various exit vectors and linkers to identify analogues that demonstrate selectivity within these families. We further use an in-cell NanoBRET assay to demonstrate that these heterobifunctional molecules are cell-permeable, form ternary complexes, and can degrade nanoluciferase-bromodomain fusions. As a first example of a CECR2 degrader, we observe that our pyrimidine-based analogues degrade endogenous CECR2 while showing a smaller effect on BPTF levels. The pyridazinone-based compounds did not degrade BPTF when observed through Western blotting, further supporting a more challenging target for degradation and a goal for future optimization.
UR - http://www.scopus.com/inward/record.url?scp=85162895533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162895533&partnerID=8YFLogxK
U2 - 10.1021/acschembio.2c00902
DO - 10.1021/acschembio.2c00902
M3 - Article
C2 - 37260298
AN - SCOPUS:85162895533
SN - 1554-8929
JO - ACS Chemical Biology
JF - ACS Chemical Biology
ER -